GLP-1 Receptor Agonist Comparison 2026

Tirzepatide (Mounjaro/Zepbound) shows the highest average weight loss in clinical trials and 2025-2026 real-world data: SURMOUNT-1 trial reported 22.5% mean body weight loss at 72 weeks for patients without diabetes on the 15mg dose; the SURMOUNT-OSA 2024 trial showed 18-20% reduction. Semaglutide (Wegovy/Ozempic off-label) reports 14.9% mean loss at 68 weeks (STEP-1 trial) on the 2.4mg dose. Liraglutide (Saxenda) shows 8% mean loss at 56 weeks. Real-world adherence-adjusted: actual weight loss tends to be 60-75% of trial-stated values due to discontinuation, dose interruptions, and tolerance development. Tirzepatide's dual GIP+GLP-1 mechanism appears responsible for the superior outcomes vs single-receptor GLP-1 agents.

List prices (April 2026, USA): Wegovy $1,349/month, Ozempic $968/month, Rybelsus $968/month, Mounjaro $1,069/month, Zepbound $1,059/month, Saxenda $1,349/month. Manufacturer savings cards reduce out-of-pocket dramatically: Novo Nordisk's Ozempic/Wegovy/Saxenda savings card brings copay to as low as $25/month for commercially insured patients; Eli Lilly's Mounjaro/Zepbound savings card brings copay to as low as $25/month with active commercial coverage and as low as $549/month without coverage (Zepbound direct-to-patient program launched September 2024). Compounded semaglutide and tirzepatide from 503A pharmacies cost $200-$450/month, but the FDA's May 2024 ruling removed both from the shortage list, leading to enforcement actions against compounders in late 2024 and ongoing through 2026; current legal status varies by formulation and manufacturer claims.

As of April 2026, Medicare does NOT cover GLP-1s for obesity treatment alone, the 2003 Medicare Modernization Act explicitly excluded weight loss drugs from Part D coverage. EXCEPTION expanded in March 2024: Wegovy IS covered when prescribed for cardiovascular risk reduction in adults with established cardiovascular disease and BMI ≥27 (CMS National Coverage Determination 280.X). The Treat and Reduce Obesity Act (TROA) seeks to repeal the exclusion and allow standard Medicare obesity coverage; the bill cleared Senate Finance committee March 2026 with bipartisan support and is scheduled for floor vote summer 2026. Estimated Medicare cost if passed: $35-$50 billion over 10 years per CBO. Medicaid coverage is state-by-state, 18 states cover Wegovy or Zepbound for obesity in 2026 (up from 11 in 2024).

Most common (10%+ patients): nausea (44% on tirzepatide, 39% semaglutide), diarrhea (21-23%), constipation (17-23%), vomiting (10-15%), abdominal pain (10-12%), reduced appetite (designed effect, but some find unpleasant). Most resolve within 4-8 weeks as dose titrates up gradually. Less common but significant (1-5%): gallbladder issues (cholecystitis, gallstones, 2.6x risk vs placebo), hair shedding (telogen effluvium, typically resolves at 6-9 months once weight stabilizes), injection site reactions, dehydration. Rare/serious (<1%): pancreatitis (5-fold risk increase, monitored via lipase), diabetic retinopathy progression in pre-existing diabetics, suicidal ideation (FDA reviewing 2024 reports, current consensus is association, not causation), thyroid C-cell tumors (boxed warning, animal studies; human signal weak; contraindicated in MEN-2 and MTC family history). NEW 2026 concern: gastroparesis cases reported in litigation; Novo and Lilly added warnings December 2024.

Weight regain is well-documented. STEP-4 trial (semaglutide): patients who continued treatment maintained 81% of weight loss; those who switched to placebo regained two-thirds of lost weight within 1 year. SURMOUNT-4 (tirzepatide): patients continuing 15mg lost an additional 5.5% in extension; placebo group regained 14% within 12 months. Mechanism: GLP-1s suppress appetite-stimulating signals; once stopped, hunger normalizes within 4-6 weeks. The 2026 clinical consensus per Endocrine Society + Obesity Medicine Association: GLP-1 therapy is a long-term/lifetime treatment for obesity (similar to antihypertensives for blood pressure), NOT a temporary weight loss tool. Discontinuation strategies that minimize regain: gradual taper over 4-6 months, structured exercise program 3+x/week, behavioral therapy, consideration of "bridging" to lower-cost oral meds (Rybelsus 14mg, naltrexone-bupropion).

Yes, but the math is harder. STEP and SURMOUNT data show 25-40% of weight lost on GLP-1s comes from lean mass (vs 20-25% from natural caloric deficit). Mitigation strategies: (1) PROTEIN, 1.0-1.2 g/lb body weight (more than the 0.8 standard since absorption is reduced); spread over 4-5 meals to maximize muscle protein synthesis given suppressed appetite. (2) RESISTANCE TRAINING, 3-4 sessions per week, progressive overload critical, without it, lean mass loss approaches 50%. (3) ADEQUATE TOTAL CALORIES, many patients on GLP-1s drop to 800-1,200 calories/day inadvertently due to appetite suppression; aim for 12 calories per pound minimum to support lean mass retention. (4) CREATINE SUPPLEMENTATION, 5g/day, well-tolerated, supports anaerobic capacity. Body composition tracking via DEXA every 3-6 months is more useful than scale weight on these medications.

Compounded semaglutide and tirzepatide were widely available 2022-2024 due to FDA-declared shortages allowing 503A and 503B pharmacies to compound. FDA removed semaglutide from shortage list April 2024 and tirzepatide October 2024, triggering enforcement actions, most major compounders (Hims, Mochi, Ro, EmpowerRx) shifted to compounded LIRAGLUTIDE or to "salt forms" (semaglutide acetate vs the FDA-approved sodium salt) which the FDA argues are NOT pharmaceutically equivalent. Q1 2026 status: ongoing litigation (Novo Nordisk v. multiple compounders, Eli Lilly v. compounders); 503B compounding remains restricted; some 503A pharmacies operate under state-level prescribing exceptions. QUALITY concerns: independent testing by Cayman Chemical 2024 found 12 of 31 sampled compounded products had concentration errors >15% from labeled dose; sterility issues reported in 8/31 samples. RECOMMENDATION: branded products via savings cards remain the safest path; verify any compounded source through state board of pharmacy registration and request third-party potency/sterility testing certificates.

Typical timeline based on STEP/SURMOUNT trial data and clinical experience: WEEK 1-4 (titration phase, 0.25mg semaglutide / 2.5mg tirzepatide): mild appetite suppression, 1-3 lbs loss, side effects peak. WEEK 5-12 (titrating to therapeutic dose): 5-10 lbs loss typical, appetite suppression noticeable, food preferences shift toward lower volume. MONTH 4-6 (therapeutic maintenance): 8-15% body weight loss range, plateau at first appears around month 5, push through with dose increase or non-pharmacologic adjustments. MONTH 7-12: peak weight loss typically reached month 12-15; total 15-22% loss for tirzepatide users adherent to lifestyle program, 12-15% for semaglutide. Patients who DO NOT lose 5%+ at month 6 are unlikely to be high responders and should consider switching mechanism (semaglutide → tirzepatide, or to combination therapy). Body composition lags behind scale weight by 4-8 weeks; DEXA at baseline + month 6 provides best progress tracking.